Investors Buy High Volume of Altimmune Call Options (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT) saw some unusual options trading activity on Tuesday. Traders acquired 18,846 call options on the stock. This represents an increase of 185% compared to the average volume of 6,618 call options.

Analyst Ratings Changes

Several research firms recently commented on ALT. Evercore ISI raised Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. B. Riley reissued a “buy” rating and set a $20.00 price objective on shares of Altimmune in a research report on Monday, August 12th. UBS Group started coverage on shares of Altimmune in a report on Tuesday. They issued a “buy” rating and a $26.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Thursday, August 22nd. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the sale, the director now owns 41,958 shares of the company’s stock, valued at $289,510.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Altimmune

Several hedge funds have recently modified their holdings of ALT. Swiss National Bank acquired a new position in Altimmune in the first quarter valued at $1,079,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Altimmune in the first quarter worth approximately $271,000. Sei Investments Co. purchased a new stake in Altimmune in the first quarter valued at approximately $479,000. SG Americas Securities LLC increased its position in Altimmune by 542.8% during the second quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after purchasing an additional 214,968 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares during the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Trading Up 0.3 %

Shares of ALT opened at $9.52 on Thursday. The firm’s 50-day moving average is $6.95 and its two-hundred day moving average is $6.89. Altimmune has a twelve month low of $2.34 and a twelve month high of $14.84. The firm has a market capitalization of $676.59 million, a P/E ratio of -6.14 and a beta of 0.09.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 52.60%. The business had revenue of $0.01 million for the quarter. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. Analysts predict that Altimmune will post -0.54 EPS for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.